THE SGLT2 INHIBITOR EMPAGLIFLOZIN REDUCES TISSUE SODIUM CONTENT IN PATIENTS WITH CHRONIC HEART FAILURE

Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, Ott C, Bramlage P, Uder M, Achenbach S, Schmieder R (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Journal of the American College of Cardiology Elsevier

Publisher: ELSEVIER SCIENCE INC

City/Town: NEW YORK

Pages Range: 585-585

Conference Proceedings Title: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

DOI: 10.1016/s0735-1097(21)01944-6

Authors with CRIS profile

Julie Kolwelter Department of Medicine 2 – Cardiology and Angiology Peter Linz Institute of Radiology Armin Michael Nagel Professur für metabolische und funktionelle MR-Bildgebung Agnes Bosch Department of Medicine 4 – Nephrology and Hypertension Christian Ott Department of Medicine 4 – Nephrology and Hypertension Michael Uder Lehrstuhl für Diagnostische Radiologie Stephan Achenbach Lehrstuhl für Innere Medizin II Roland Schmieder Professur für Innere Medizin (Nephrologie)

Involved external institutions

IPPMed - Institut für Pharmakologie und Präventive Medizin GmbH

Germany (DE)

How to cite

APA:

Kolwelter, J., Kannenkeril, D., Linz, P., Jung, S., Nagel, A.M., Bosch, A.,... Schmieder, R. (2021). THE SGLT2 INHIBITOR EMPAGLIFLOZIN REDUCES TISSUE SODIUM CONTENT IN PATIENTS WITH CHRONIC HEART FAILURE. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (pp. 585-585). NEW YORK: ELSEVIER SCIENCE INC.

MLA:

Kolwelter, Julie, et al. "THE SGLT2 INHIBITOR EMPAGLIFLOZIN REDUCES TISSUE SODIUM CONTENT IN PATIENTS WITH CHRONIC HEART FAILURE." Proceedings of the 70th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) NEW YORK: ELSEVIER SCIENCE INC, 2021. 585-585.

BibTeX: Download